nelfinavir has been researched along with indinavir sulfate in 286 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 56 (19.58) | 18.2507 |
| 2000's | 195 (68.18) | 29.6817 |
| 2010's | 31 (10.84) | 24.3611 |
| 2020's | 4 (1.40) | 2.80 |
| Authors | Studies |
|---|---|
| Fromm, MF; Kim, RB; Leake, B; Roden, DM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR | 1 |
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Blaschke, TF; Giacomini, KM; Gorset, W; Kroetz, DL; Washington, CB; Zhang, L | 1 |
| Choo, EF; Imamura, H; Kim, RB; Leake, B; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Almond, MR; Bock, WJ; Cleary, DG; Furfine, ES; Hazen, RJ; Kazmierski, WM; Salituro, FG; Spaltenstein, A; Tung, RD; Wright, LL | 1 |
| Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
| Chen, IW; Darke, PL; Dorsey, BD; Emini, EA; Hoffman, JM; Holloway, MK; Huff, JR; Kuo, LC; Levin, RB; Lin, JH; McDaniel, SL; McDonough, C; Michelson, SR; Newton, CL; Olsen, DB; Rutkowski, CA; Schleif, WA; Stahlhut, MW; Vacca, JP; Zugay-Murphy, JA | 1 |
| Classon, B; Hallberg, A; Mühlman, A; Samuelsson, B | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Gorey-Feret, LJ; Murphy, PV; O'Brien, JL; Smith, AB | 1 |
| Danielson, UH; Hallberg, A; Hämäläinen, M; Karlén, A; Markgren, PO; Samuelsson, B; Schaal, W | 1 |
| Kim, RB; Leake, BF; Tirona, RG; Wolkoff, AW | 1 |
| Freire, E; Muzammil, S; Ross, P | 1 |
| Blum, LE; Clemente, JC; Dunn, BM; Goodenow, MM; Hemrajani, R | 1 |
| Furfine, ES; Hanlon, MH; Hazen, RJ; Miller, JF; Ray, JA; Robinson, L; Samano, V; Spaltenstein, A | 1 |
| Agbandje-McKenna, M; Clemente, JC; Dunn, BM; Goodenow, MM; Govindasamy, L; Hemrajani, R; McKenna, R; Moose, RE; Reutzel, R; Whitford, LR | 1 |
| Danielson, UH; Shuman, CF; Vrang, L | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Bertucci, C; Cimitan, S; Danielson, UH; Lindgren, MT | 1 |
| Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A | 1 |
| Garg, R; Patel, D | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Agbandje-McKenna, M; Clemente, JC; Coman, RM; Dunn, BM; Goodenow, MM; Govindasamy, L; Janka, LK; Jeung, JA; Leelamanit, W; McKenna, R; Nukoolkarn, S; Thiaville, MM | 1 |
| Das, D; Gatanaga, H; Ghosh, AK; Grum-Tokars, V; Hussain, AK; Koh, Y; Kovalevsky, AY; Leshchenko, S; Li, J; Maeda, K; Mitsuya, H; Sridhar, PR; Walters, DE; Weber, IT; Wedekind, JE | 1 |
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Brenner, BG; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P | 1 |
| Dandache, S; Parkin, N; Schapiro, JM; Sévigny, G; Stranix, BR; Wainberg, MA; Wu, JJ; Yelle, J | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| Hayashi, H; Mimoto, T; Nojima, S; Shintani, M; Takaku, H; Terashima, K | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Carmen Villaverde, M; Domínguez, JL; Gossas, T; Helena Danielson, U; Sussman, F | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Diederich, WE; Kuhnert, M; Steuber, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Al-Abed, Y; Altiti, A; Bloom, O; Cheng, KF; Coleman, TR; Crawford, JM; Diamond, B; Grant, C; He, M; Jeganathan, V; Kowal, C; Meurice, N; Papatheodorou, A; Sun, S; VanPatten, S; Volpe, BT | 1 |
| Anderson, KS; Cabeza de Vaca, I; Deshmukh, M; Ghahremanpour, MM; Ippolito, JA; Jorgensen, WL; Liosi, ME; Tirado-Rives, J; Zhang, CH | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Blair, ED; Darby, G; Furfine, ES; Maschera, B; Myers, R; Palú, G; Tisdale, M; Wright, LL | 1 |
| Deeks, SG; Holodniy, M; Kahn, JO; Smith, M | 1 |
| Kuritzkes, DR; McDonald, CK | 1 |
| Cao, Y; Ho, DD; Markowitz, M; Saksela, K; Vesanen, M | 1 |
| Ferrando, S; Rabkin, JG | 1 |
| Grodesky, MJ; Klaus, BD | 1 |
| Chiba, N; Hayashi, H; Shintani, M; Ueno, T | 1 |
| Burton, S; Carr, A; Chisholm, DJ; Cooper, DA; Freund, J; Law, M; Samaras, K | 1 |
| Vondrasek, J; Wlodawer, A | 1 |
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Saag, MS; Schooley, RT | 1 |
| Boden, D; Markowitz, M | 1 |
| Blaschke, TF; Duran, GE; Man, MC; Sikic, BI; Washington, CB | 1 |
| Chronister, CL; Gurwood, AS | 1 |
| Brew, BJ; Markus, R | 1 |
| Lien, EJ; Ren, S | 1 |
| Holtzer, CD; Varav, H | 1 |
| Kuper, JJ; Malaty, LI | 1 |
| Furrer, H; Malinverni, R | 1 |
| Carver, PL; Cinti, SK; Kaul, DR; Kazanjian, PH | 1 |
| Dubreuil, L; Gérard, Y; Maulin, L; Mouton, Y | 1 |
| Efron, B; Lawrence, J; Merigan, TC; Montoya, J; Pesano, R; Schapiro, J; Winslow, D; Winters, M; Zolopa, A | 1 |
| Becker, M; Chesney, M; Deeks, SG; Grant, RM; Hellmann, NS; Parkin, NT; Petropoulos, CJ; Symonds, W; Volberding, PA | 1 |
| Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Verweij-van Wissen, CP; Wuis, EW | 1 |
| Brendel, V; Craig, C; Hsu, P; Patick, AK; Shafer, RW | 1 |
| Barnett, SH; Gallant, JE; Hall, CS; Moore, RD; Raines, CP | 1 |
| Clough, LA; D'Agata, E; Haas, DW; Raffanti, S | 1 |
| Cheseaux, JJ; Darioli, R; Glauser, MP; Halfon, P; Marcovina, SM; Mooser, V; Nicod, P; Périard, D; Reymond, MJ; Sudre, P; Telenti, A | 1 |
| Kessler, CM; Racoosin, JA | 1 |
| Heald, AE; Heffron, S; Schiffman, SS; Zervakis, J | 1 |
| Back, DJ; Eagling, VA; Profit, L | 1 |
| Berger, J; Li, Z; MacNaul, K; Moller, DE; Szalkowski, D; Zhang, B | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Matsumura, Y; Takada, K; Yamaji, H; Yoshikawa, Y | 1 |
| Clumeck, N | 1 |
| Addo, M; Berthold, HK; Parhofer, KG; Ritter, MM; Rockstroh, JK; Schliefer, K; Spengler, U; Wasmuth, JC | 1 |
| Fletcher, CV; Kawle, SP; Remmel, RP; Weller, D | 1 |
| Bendfeldt, K; Bode, H; Fromm, M; Riecken, EO; Schmidt, W; Schulzke, JD; Ullrich, R; Wahnschaffe, U; Zippel, T | 1 |
| Butcher, D; Duong, P; Greene, J; Markson, L | 1 |
| Danielson, UH; Hämäläinen, M; Markgren, PO | 1 |
| Arnedo, A; Gómez, CJ; Roca, B | 1 |
| Anderson, C; Craik, CS; Jolly, DJ; Todd, S | 1 |
| Heinrikson, RL; Tomasselli, AG | 1 |
| Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL; Zalma, A | 1 |
| Gulick, R | 1 |
| Delfraissy, JF; Frau, E; Furlan, V; Goujard, C; Labetoulle, M; Lantz, O; Lecointe, D; Niessen, F; Offret, H; Rogier, H | 1 |
| Butler, KM; Clarke, SM; Condon, S; Healy, CM; Mulcahy, F | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Agostoni, F; Angeli, E; Atzori, C; Cargnel, A; Mainini, A; Micheli, V | 1 |
| Alessi, F; Bonfanti, P; Carradori, S; Di Cintio, E; Faggion, I; Fortuna, P; Gabbuti, A; Ghiselli, G; Landonio, S; Martinelli, C; Parazzini, F; Pusterla, L; Quirino, T; Timillero, L; Valsecchi, L | 1 |
| Aladdin, H; Dickmeiss, E; Gerstoft, J; Hede, A; Jørgensen, LB; Katzenstein, TL; Nielsen, C; Nielsen, H | 1 |
| Decker, CF; Martin, GJ; Smith, JH | 1 |
| Israel, DS; Monroe, S; Pakyz, A; Polk, RE; Slain, D | 1 |
| Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R | 1 |
| Croom, DK; Furfine, ES; Lenhard, JM; Reynolds, DJ; Spaltenstein, A; Weiel, JE | 1 |
| Biryahwaho, B; Dondero, T; Downing, R; Hu, DJ; Lal, R; Mastro, T; Nkengasong, J; Pieniazek, D; Rayfield, M; Soriano, V; Tanuri, A; Wiktor, SZ | 1 |
| Ammassari, A; Baldini, F; Cingolani, A; De Luca, A; Di Giambenedetto, S; Murri, R | 1 |
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| D'Aquila, RT; Martinez-Picado, J; Savara, AV; Shi, L; Sutton, L | 1 |
| Freire, E; Luque, I; Todd, MJ; Velázquez-Campoy, A | 1 |
| Tavel, JA | 1 |
| Kawaguchi, Y; Matsumura, Y; Ohtani, A; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Burger, DM; den Hartigh, J; Hoetelmans, RM; Hugen, PW; Kroon, FP; Schippers, EF; Visser, LG | 1 |
| Busch, M; Hecht, FM; Kahn, J; Levy, JA; Martinez-Marino, B; Ong, JC; Stranford, SA | 1 |
| Aungst, BJ; Bulgarelli, JP; Nguyen, NH; Oates-Lenz, K | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R | 1 |
| Bode, H; Fromm, M; Riecken, EO; Schmidt, W; Schulzke, JD; Ullrich, R | 1 |
| Bouley, M; Briere, C; Padoin, C; Petitjean, O; Tod, M | 1 |
| Gatell, J; Lazzarin, A; Lundgren, JD; Miller, V; Mocroft, A; Parkin, JM; Phillips, AN; Roge, B; van Lunzen, J; Weber, R | 1 |
| Koranyi, KI; Nahata, MC; Temple, ME | 1 |
| Dubé, MP; Forthal, DN; Haubrich, R; Hellmann, NS; Keiser, PH; Kemper, CA; Leedom, J; Leibowitz, M; Lie, YS; McCutchan, JA; Richman, D; Rigby, A; Smith, DS; Witt, MD | 1 |
| Kessler, HA; Nerad, JL | 1 |
| Freire, E; Todd, MJ; Vega, S; Velazquez-Campoy, A | 1 |
| Levin, J | 1 |
| Mascolini, M | 1 |
| Back, DJ; Davey, R; Hoggard, PG; Jones, K; Khoo, S; Sales, SD | 1 |
| Iwamoto, A; Kotaki, H; Nakamura, T; Yamada, H | 1 |
| Colebunders, R; de Mey, I; Dedes, N; Dreezen, C; Finazzi, R; Florence, E; Koitz, G; Molenberghs, G; Schrooten, W; Youle, M | 1 |
| Funk, MB; Klingebiel, T; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Danielson, UH; Gertow, K; Hämäläinen, M; Karlsson, R; Lindgren, MT; Markgren, PO | 1 |
| Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M | 1 |
| Mitchell, SM; Newson, RB; Zambarakji, HJ | 1 |
| Beall, GN; Chang, ES; Liu, YT; Tetreault, DD | 1 |
| Adler, B; James, I; John, M; Mallal, S; McKinnon, E; Nolan, D; Roff, G; Upton, R; Vasikaran, S | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Cauda, R; Leone, G; Lucia, MB; Rutella, S; Vella, S | 1 |
| Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P | 1 |
| Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Thomas, L | 1 |
| Back, DJ; Bray, PG; Davey, RA; Jones, K; Khoo, SH; Meaden, ER; Ward, SA | 1 |
| Chalifoux, L; Chen, ZW; Enimi, EA; Gastron, M; Henckler, B; Letvin, NL; Miller, M; Sehgal, N; Sehgal, P; Shen, L; Shen, Y; Simon, M; Zhou, D | 1 |
| Burger, DM; Chesney, MA; Danner, SA; de Wolf, F; Hoetelmans, RM; Hugen, PW; Jambroes, M; Kauffmann, RH; Lange, JM; Meenhorst, PL; Nieuwkerk, PT; Schneider, MM; Schrey, G; Sprangers, MA; Sprenger, HG; van Der Ende, ME | 1 |
| Bartlett, JG; del Rio, C | 1 |
| Gantke, B; Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Aubertin, AM; Gaucher, B; Greiner, J; Guedj, R; Rouquayrol, M; Vierling, P | 1 |
| Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS | 1 |
| Bower, M; Gazzard, BG; Johnson, MA; Lampe, F; Mandalia, S; Matthews, GV; Nelson, MR; Phillips, AN; Sabin, CA | 1 |
| Barbour, JD; Deeks, SG; Grant, RM; Martin, JN | 1 |
| Craig, C; Perrin, L; Popescu, M; Rickenbach, M; Taffe, P; Yerly, S | 1 |
| Back, DJ; Eagling, VA; Whitcombe, IW; Wiltshire, H | 1 |
| Gao, W; Kishida, T; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Abrams, DI; Aweeka, FT; Benowitz, NL; Hilton, JF; Kosel, BW; Lizak, PS; Shade, SB | 1 |
| Burger, DM; de Groot, R; Geelen, SP; Hartwig, NG; Hop, WC; Osterhaus, AD; Scherpbier, HJ; Schutten, M; van Lochem, EG; van Rossum, AM; Weemaes, CM; Wolfs, TF | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 2 |
| de Groot, R; Fraaij, PL; van Rossum, AM | 1 |
| Jain, RG; Lenhard, JM | 1 |
| Piliero, PJ | 1 |
| Goodsell, DS; Morris, GM; Olson, AJ; Sanner, MF; Stoffler, D | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Choo, PW; Colson, AE; Keller, MJ; Pettus, PT; Platt, R; Sax, PE | 1 |
| Freire, E; Vega, S; Velazquez-Campoy, A | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
| Gazzard, BG; Mandalia, S; Nelson, MR; Pozniak, AL; Walsh, JC | 1 |
| Gao, W; Kageyama, M; Kimura, K; Kishida, T; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Bennett, KK; Hammer, SM; Labbé, L; Lu, JF; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB | 1 |
| Bergshoeff, AS; Burger, DM; De Groot, R; Fraaij, PL; Geelen, SP; Hartwig, NG; Hugen, PW; van Rossum, AM; Weemaes, CM; Wolfs, TF | 1 |
| Aweeka, FT; Chi, J; Jayewardene, AL; Motoya, T; Stone, JA | 1 |
| Hashida, S; Iga, M; Matsuda, Z; Morishita, K; Nagai, Y; Okayama, A; Sugiura, W; Tsubouchi, H | 1 |
| Martínez Losada, EJ; Pedrol Clotet, E; Rodellar Oncins, MT; Soler Sendra, A | 1 |
| Carr, A; Chisholm, DJ; Cooper, DA; Gan, SK; Kraegen, EW; Samaras, K; Thompson, CH | 1 |
| Deutsch, P; Havlir, D; Kerr, B; Lewis, RH; Peng, Y; Riddler, SA; Saah, A; Squires, KE; Wynne, LH; Yeh, K; Zhong, L | 1 |
| Gaucher, B; Greiner, J; Roche, D; Rouquayrol, M; Vierling, P | 1 |
| Bashan, N; Ben-Romano, R; Klip, A; Riesenberg, K; Rudich, A; Schlaeffer, F; Török, D; Vanounou, S | 1 |
| de Araujo, M; Seguro, AC | 1 |
| Bennett, KK; Hammer, SM; Labbé, L; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB | 1 |
| Fukumoto, K; Fukushima, K; Gao, W; Inoue, Y; Kageyama, M; Nishimura, A; Shibata, N; Tadano, J; Takada, K; Yamasaki, D; Yoshikawa, Y | 1 |
| Brodt, HR; Findhammer, S; Helm, EB; Nolte, B; Wolf, T | 1 |
| Arcidiacono, MV; Cozzolino, M; Dusso, AS; Tebas, P; Vidal, M; Yarasheski, KE | 1 |
| Bratt, G; Ståhle, L | 1 |
| Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M | 1 |
| Aziz, D; Bean, P; Graziano, FM; Neudeck, BL; Urban, AW | 1 |
| Calza, L; Manfredi, R | 1 |
| DiFrancesco, R; Frerichs, VA; Keil, K; Morse, G | 1 |
| Burger, DM; Droste, JA; Verweij-Van Wissen, CP | 1 |
| Bartlett, JG; Celentano, DD; Lai, H; Lai, S; Lima, JA; Margolick, J; Ren, S; Vlahov, D | 1 |
| Aarnoutse, R; Brinkman, K; Burger, D; Gyssens, I; Hugen, P; Kroon, F; Lange, J; Prins, J; Reiss, P; Richter, C; Schneider, M; Schreij, G | 1 |
| Aweeka, FT; Beckerman, KP; Hayashi, S; Homma, M; Kosel, BW | 1 |
| Hruz, PW; Koster, JC; Nichols, CG; Qiu, H; Remedi, MS | 1 |
| DeGruttola, V; Foulkes, AS | 1 |
| Collier, AC; Dehlinger, M; Demeter, LM; Erice, A; Eron, JJ; Eshleman, SH; Feinberg, JE; Fischl, MA; Giuliano, M; Hammer, SM; Morse, GD; Ribaudo, HJ; Saag, MS; Vella, S | 1 |
| Aberg, JA; Abrams, DI; Aweeka, FT; Bacchetti, P; Benowitz, NL; Bredt, BM; Deeks, SG; Elbeik, TA; Hilton, JF; Kosel, B; Leiser, RJ; McCune, JM; Mitchell, TF; Mulligan, K; Schambelan, M; Shade, SB | 1 |
| Fakruddin, JM; Laurence, J | 1 |
| Brady, M; Cox, S; Crim, L; Gerber, N; Koranyi, K; Utkin, I; Walson, PD | 2 |
| Ailhaud, G; Azoulay, S; Dani, C; Duval, D; Guedj, R; Vernochet, C | 1 |
| Adjé-Touré, CA; Borget, MY; Bouchez, JM; Cheingsong, R; Chorba, T; Eholié, S; Ekpini, RE; Garcìa-Lerma, JG; Heneine, W; Maurice, C; Nkengasong, JN; Nolan, M; Otten, RA; Sassan-Morokro, M | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Sterlingot, H | 1 |
| Bouvet, E; Chêne, G; Cottalorda, J; de Boever, CM; Journot, V; Le Moing, V; Leport, C; Peytavin, G; Préau, M; Raffi, F | 1 |
| Aubertin, AM; Gaucher, B; Greiner, J; Roche, D; Rouquayrol, M; Vierling, P | 1 |
| Bassett, R; Currier, JS; DeGruttola, V; Demeter, LM; Eron, JJ; Fischl, MA; Hammer, SM; Mellors, JW; Morse, GD; Santana, JL; Squires, KE | 1 |
| Collier, A; DiCenzo, R; DiFrancecso, R; Feinberg, J; Fischl, MA; Forrest, A; Morse, GD; Ribaudo, H | 1 |
| Gupta, A; Mao, Q; Unadkat, JD; Zhang, Y | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Drews, G; Düfer, M; Krippeit-Drews, P; Neye, Y | 2 |
| Albert, I; Bénoliel, S; Brun-Vézinet, F; Duval, X; Ecobichon, JL; Leport, C; Mentré, F; Peytavin, G; Vildé, JL | 1 |
| Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Demeter, LM; Erice, A; Eshleman, SH; Fischl, MA; Hammer, SM; Hellmann, NS; Ribaudo, HJ | 1 |
| Agrawal, KC; Ali, M; Mondal, D; Pradhan, L | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
| Klein, HH; Meier, M; Schütt, M; Zhou, J | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Bassetti, D; Bassetti, M; Cinelli, R; Cruciani, M; Di Gennaro, G; Gatti, G; Tirelli, U; Vaccher, E | 1 |
| Bedoni, AJ; Figueiredo, RM; Garcia, MT; Moretti, ML; Papaiordanou, PM; Resende, MR | 1 |
| Back, DJ; Janneh, O; Jones, SP; Pirmohamed, M | 1 |
| Bruno, R; Filice, G; Maiocchi, L; Sacchi, P; Zocchetti, C | 1 |
| Burger, DM; Droste, JA; Hekster, YA; Koopmans, PP | 1 |
| Chai, H; Chen, C; Li, M; Lin, PH; Lumsden, AB; Yan, S; Yang, H; Yao, Q | 1 |
| Bonnet, B; Diquet, B; Duval, X; Goujard, C; Katlama, C; Legrand, M; Leport, C; Mentré, F; Panhard, X; Peytavin, G; Salmon-Céron, D; Taburet, AM; Vincent, I | 1 |
| Backman, JT; Granfors, MT; Kajosaari, LI; Laitila, J; Neuvonen, PJ; Wang, JS | 1 |
| Afonso, A; Aguiar, RS; Arruda, MB; Brindeiro, PA; Brindeiro, RM; Gonzalez, LMF; Soares, MA; Tanuri, A | 1 |
| Crane, HM; Kitahata, MM; Van Rompaey, SE | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| Aymard, G; Bergmann, JF; Mahé, I; Mouly, S; Rizzo-Padoin, N; Salvat, C; Simoneau, G; Verstuyft, C | 1 |
| Alviano, CS; dos Santos, AL; Kneipp, LF; Palmeira, VF | 1 |
| Abecasis, AB; Bacheler, LT; Camacho, RJ; Carvalho, AP; Deforche, K; Gomes, P; McKenna, P; Vandamme, AM | 1 |
| de Hoon, J; Van Wijngaerden, E; Verbesselt, R | 1 |
| Biollaz, J; Buclin, T; Colombo, S; Décosterd, LA; Eap, CB; Furrer, H; Lee, BL; Telenti, A | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Ariyoshi, K; Bouzas, MB; Brigido, LF; Cahn, P; Camacho, R; Cane, P; Carvalho, AP; Clarke, J; Deforche, K; Grossman, Z; Harrigan, PR; Holguin, A; Kantor, R; Katzenstein, DA; Moreau, Y; Morris, L; Phanuphak, P; Pillay, D; Rodrigues, R; Rudich, H; Shafer, RW; Shapiro, JM; Silander, T; Sirivichayakul, S; Snoeck, J; Soares, MA; Soriano, V; Sugiura, W; Tanuri, A; Van Laethem, K; Vandamme, AM; Weber, J; Wynhoven, B | 1 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| Beijnen, JH; Bosch, TM; Cornelissen, M; Crommentuyn, KM; Huitema, AD; Jurriaans, S; Kloosterboer, N; Lange, JM; Mul, FP; Prins, JM; Sankatsing, SU; Schuitemaker, H | 1 |
| Chew, N; Cotter, E; Doran, PP; Malizia, AP; Powderly, WG | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Auclair, M; Béréziat, V; Bodemer, C; Capeau, J; Caron, M; Donadille, B; Guerci, B; Lascols, O; Laville, M; Narbonne, H; Vigouroux, C | 1 |
| Diquet, B; Goujard, C; Legrand, M; Mentré, F; Panhard, X; Taburet, AM | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Coman, RM; Dunn, BM; Fernandez, MA; Gilliland, CT; Goodenow, MM; McKenna, R; Robbins, AH; Sochet, AA | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Chao, Y; Grigorian, A; Hurford, R; Langford, TD; Patrick, C | 1 |
| Louis, JM; Sayer, JM | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Chow, WA; Guan, M; Jiang, C | 1 |
| Abecasis, AB; Camacho, RJ; Santos, AF; Soares, MA; Vandamme, AM | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Bhasin, VK; Bhattacharya, A; Mishra, LC; Sharma, M | 1 |
| Annaert, P; Augustijns, P; Camus, S; Ye, ZW | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| Aguiar, CV; Braga Neto, MB; Brito, GA; Guerrant, RL; Lima, AA; Maciel, JG; Oliveira, BM; Oriá, RB; Sevilleja, JE; Warren, CA | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP | 1 |
| Brandmann, M; Dringen, R; Schmidt, MM; Tulpule, K | 1 |
| Arend, C; Brandmann, M; Dringen, R | 1 |
| Anwar, K; Ismail, WI; King, JA; Pillay, TS | 1 |
| Brandmann, M; Dringen, R; Hohnholt, MC; Petters, C | 1 |
| Anderson, AM; Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Gottlieb, GS; Tchounga, BK; Tegbe, J; Vitoria, M | 1 |
| Haugaard, SB | 1 |
| Branquinha, MH; D Avila-Levy, CM; Menna-Barreto, RF; Sangenito, LS; Santos, AL | 1 |
| Battista, C; Howell, BA; Mettetal, JT; Siler, SQ; Stahl, SH; Watkins, PB; Woodhead, JL; Yang, K | 1 |
| Jahagirdar, V; McNay, EC; Pearson-Leary, J; Sage, J | 1 |
| Andrulewicz-Botulinska, E; Hlebowicz-Sarat, K; Karna, E; Palka, JA; Szoka, L | 1 |
| Wang, RG; Zhang, HX; Zheng, QC | 1 |
| Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M | 1 |
| Aubertin, AM; Greiner, J; Roche, D; Vierling, P | 1 |
29 review(s) available for nelfinavir and indinavir sulfate
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
HIV-1 protease inhibitors. A review for clinicians.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1997 |
Human immunodeficiency virus type 1 protease inhibitors.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Interactions; Drug Resistance; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Sulfonic Acids | 1997 |
A 'second life' agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Attitude to Health; Drug Approval; Drug Costs; Drug Interactions; Health Policy; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Life Style; Nelfinavir; Primary Prevention; Ritonavir; Saquinavir; United States; United States Food and Drug Administration; Viral Load | 1997 |
[Clinical application of HIV protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1998 |
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
Topics: Binding Sites; Biophysics; Drug Design; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Models, Molecular; Nelfinavir; Nuclear Magnetic Resonance, Biomolecular; Protein Structure, Secondary; Quantum Theory | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Resistance to human immunodeficiency virus type 1 protease inhibitors.
Topics: Carbamates; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Nelfinavir; Pyridines; Pyrones; Ritonavir; Saquinavir; Structure-Activity Relationship; Sulfonamides | 1998 |
Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Retina; Retinal Diseases; Ritonavir; Saquinavir | 1998 |
Development of HIV protease inhibitors: a survey.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Structure-Activity Relationship | 1998 |
Simultaneous use of two protease inhibitors in HIV infection.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Drug interactions of HIV protease inhibitors.
Topics: Anti-Infective Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Topics: Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Lipodystrophy; Nelfinavir; Ritonavir; Saquinavir | 1999 |
[HIV protease inhibitors: drug interactions].
Topics: Anti-HIV Agents; Contraindications; Drug Interactions; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Risk Factors; Ritonavir; Saquinavir | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
HIV protease as a target for retrovirus vector-mediated gene therapy.
Topics: Amino Acid Sequence; Carbamates; Furans; Genetic Therapy; Genetic Vectors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lentivirus; Models, Molecular; Molecular Structure; Nelfinavir; Retroviridae; Ritonavir; Saquinavir; Sulfonamides; Transfection | 2000 |
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as Topic; Computer-Aided Design; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides | 2000 |
The choice of HIV protease inhibitor: indinavir is currently the best option.
Topics: Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Treatment Outcome | 1999 |
Ongoing trials in HIV protease inhibitors.
Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration | 2000 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir | 2002 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Hepatotoxicity and nelfinavir: a meta-analysis.
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Nelfinavir | 2005 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Anti-HIV drugs for cancer therapeutics: back to the future?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cidofovir; Cytosine; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Neoplasms; Organophosphonates; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2009 |
Antiretroviral therapy response among HIV-2 infected patients: a systematic review.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Female; HIV Infections; HIV-2; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Ritonavir; Treatment Outcome | 2014 |
Alteration in pancreatic islet function in human immunodeficiency virus.
Topics: Carbamates; Furans; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Nelfinavir; Ritonavir; Sulfonamides | 2014 |
33 trial(s) available for nelfinavir and indinavir sulfate
| Article | Year |
|---|---|
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
Topics: Adult; Drug Resistance; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Polypharmacy; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir | 1999 |
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir | 1999 |
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Diseases; Lamivudine; Male; Nelfinavir; Patient Compliance; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 2000 |
Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
Topics: Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Drug Therapy, Combination; Foscarnet; Ganciclovir; HIV Protease Inhibitors; Humans; Incidence; Indinavir; Nelfinavir; Outcome Assessment, Health Care; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Variability in activity of hepatic CYP3A4 in patients infected with HIV.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; HIV Infections; Humans; Indinavir; Liver; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir | 2000 |
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Drug Tolerance; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Pilot Projects; Pravastatin; Ritonavir; Saquinavir; Treatment Outcome | 2000 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Viral Load | 2001 |
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Prospective Studies; Ritonavir; Saquinavir; Treatment Outcome; Viral Load | 2001 |
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; Erectile Dysfunction; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Multivariate Analysis; Nelfinavir; Prevalence; Risk Factors; Ritonavir; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 2001 |
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Time; Viral Load; Zidovudine | 2001 |
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Topics: Adult; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Mixed Function Oxygenases; Nelfinavir; Orosomucoid; Saquinavir; Sulfonamides | 2001 |
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2002 |
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Topics: Adult; Appetite Stimulants; Dronabinol; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Marijuana Smoking; Middle Aged; Nelfinavir | 2002 |
Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Netherlands; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Topics: Adult; Biological Availability; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Saquinavir; Sulfonamides | 2002 |
Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Nelfinavir; Patient Compliance; RNA, Viral; Viral Load | 2002 |
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
Topics: Adult; Area Under Curve; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir | 2002 |
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Bayes Theorem; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Indinavir; Male; Models, Biological; Nelfinavir; Oxazines; Population Surveillance; Treatment Failure | 2003 |
Sildenafil does not alter nelfinavir pharmacokinetics.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Erectile Dysfunction; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Piperazines; Purines; Ritonavir; Saquinavir; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2003 |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure | 2003 |
Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Cross-Sectional Studies; Drug Monitoring; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; RNA, Viral | 2003 |
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Prospective Studies; Viral Load | 2003 |
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Nelfinavir; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.
Topics: Administration, Oral; Cannabinoids; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dronabinol; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; RNA, Viral; Viral Load | 2003 |
A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV-1; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Phenotype; Reverse Transcriptase Inhibitors; Treatment Failure | 2003 |
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Blotting, Western; Female; Half-Life; HIV Infections; Humans; Indinavir; Male; Nelfinavir | 2004 |
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Phenotype; Stavudine; Treatment Failure; Zidovudine | 2004 |
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Multicenter Studies as Topic; Nelfinavir; Patient Compliance; Prospective Studies; Ritonavir; Viral Load | 2005 |
Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Models, Biological; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Tissue Distribution; Zidovudine | 2007 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
224 other study(ies) available for nelfinavir and indinavir sulfate
| Article | Year |
|---|---|
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Male; Mice; Nelfinavir; Saquinavir | 1998 |
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication | 1998 |
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carbon Radioisotopes; Carrier Proteins; Dose-Response Relationship, Drug; Gene Expression; HeLa Cells; HIV Protease Inhibitors; Humans; Indinavir; Membrane Proteins; Multidrug Resistance-Associated Proteins; Nelfinavir; Organic Cation Transporter 1; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Saquinavir; Tetraethylammonium; Tumor Cells, Cultured | 2000 |
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Caco-2 Cells; Dibenzocycloheptenes; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Mice; Quinolines; Testis | 2000 |
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Topics: Anti-HIV Agents; Drug Design; HIV Protease Inhibitors; Thiazoles | 2000 |
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
Topics: Animals; Antiviral Agents; Cattle; Cell Culture Techniques; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Haplorhini; HIV Protease Inhibitors; HIV-1; Humans; Indans; Male; Piperazines; Protein Binding; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Urinary Calculi | 2000 |
Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
Topics: Cell Line; Cloning, Molecular; Cytopathogenic Effect, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Magnetic Resonance Spectroscopy; Structure-Activity Relationship; Thiophenes | 2001 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds.
Topics: Aspartic Acid Endopeptidases; Binding Sites; Drug Design; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Mannose; Molecular Conformation; Structure-Activity Relationship | 2002 |
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
Topics: Biosensing Techniques; HIV Protease; HIV Protease Inhibitors; Kinetics; Protein Binding; Structure-Activity Relationship; Surface Plasmon Resonance; Urea | 2002 |
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antitubercular; Carrier Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Complementary; Estradiol; Genes, Reporter; Hepatocytes; Humans; In Vitro Techniques; Kinetics; Liver-Specific Organic Anion Transporter 1; Membrane Transport Proteins; Organic Anion Transporters, Sodium-Dependent; Organic Cation Transporter 1; Plasmids; Pregnane X Receptor; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rifampin; Symporters; Transcriptional Activation; Transfection | 2003 |
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Topics: Binding Sites; Binding, Competitive; Catalysis; Drug Resistance, Viral; Enzyme Stability; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Chemical; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Saquinavir; Structure-Activity Relationship; Thermodynamics | 2003 |
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Topics: Alanine; Anti-HIV Agents; Asparagine; Aspartic Acid; Binding Sites; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoleucine; Kinetics; Methionine; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Valine | 2003 |
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Topics: Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Multiple, Viral; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Molecular Structure; Mutation; Rats; Structure-Activity Relationship; Sulfonamides | 2004 |
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
Topics: Binding Sites; Crystallography, X-Ray; Dimerization; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Indinavir; Kinetics; Models, Molecular; Molecular Structure; Mutation; Protein Structure, Tertiary; Thermodynamics | 2004 |
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
Topics: Biosensing Techniques; Cells, Cultured; Cluster Analysis; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Principal Component Analysis; Quantitative Structure-Activity Relationship; Virus Replication | 2004 |
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
Topics: Absorption; Anti-HIV Agents; Antineoplastic Agents; Binding Sites; Biosensing Techniques; Blood Proteins; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Lipids; Membranes, Artificial; Orosomucoid; Serum Albumin; Surface Plasmon Resonance; Taxoids | 2005 |
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication | 2005 |
Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
Topics: Drug Design; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Ligands; Molecular Conformation; Pyrimidinones; Quantitative Structure-Activity Relationship | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Oligopeptides; Polymorphism, Genetic; Pyridines; Structure-Activity Relationship | 2006 |
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2006 |
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Topics: Amino Acid Sequence; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine | 2007 |
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Mutation; Phenotype; Sulfonamides; Viral Proteins | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Topics: Animals; Dogs; Drug Design; Hepatocytes; HIV Protease Inhibitors; HIV-1; Humans; Molecular Structure; Mutation; Phenylbutyrates; Sensitivity and Specificity; Structure-Activity Relationship | 2008 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
Topics: Biosensing Techniques; Catalytic Domain; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen-Ion Concentration; Kinetics; Models, Molecular; Surface Plasmon Resonance | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Topics: Aspartic Acid Endopeptidases; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Protease Inhibitors; Indinavir; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2014 |
Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies.
Topics: Animals; Antibodies, Antinuclear; DNA; Drug Discovery; Female; HIV Protease Inhibitors; Humans; Kidney Glomerulus; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Models, Molecular | 2016 |
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
Topics: | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Kinetics; Mutagenesis; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Sulfonic Acids | 1996 |
Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; DNA Primers; Drug Therapy, Combination; HIV-1; Humans; Indinavir; Isoquinolines; Leukocytes, Mononuclear; Nelfinavir; Polymerase Chain Reaction; Ritonavir; RNA Splicing; RNA, Messenger; RNA, Viral; Sulfonic Acids; Virus Replication; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Education as Topic; Primary Nursing; Ritonavir; Saquinavir | 1998 |
[Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Topics: Diabetes Complications; Diabetes Mellitus; HIV Infections; HIV Protease Inhibitors; Humans; Hyperglycemia; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1997 |
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Topics: Adult; Anti-HIV Agents; Body Composition; Cross-Sectional Studies; Diabetes Mellitus; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Insulin Resistance; Lipodystrophy; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Syndrome | 1998 |
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Topics: Anti-HIV Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Indinavir; Leukemia, Erythroblastic, Acute; Nelfinavir; Paclitaxel; Ritonavir; Saquinavir; Sarcoma; Tumor Cells, Cultured; Uterine Neoplasms; Vinblastine | 1998 |
HIV-1 peripheral neuropathy and combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nelfinavir; Nevirapine; Peripheral Nervous System Diseases; Saquinavir; Zidovudine | 1998 |
Report updates recommendations for health workers exposed to HIV.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Occupational Exposure; Practice Guidelines as Topic; United States; United States Public Health Service; Zidovudine | 1998 |
Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Inflammatory Agents; Antitubercular Agents; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Inflammation; Nelfinavir; Prednisone; Tuberculosis | 1999 |
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reproducibility of Results; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 1999 |
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Failure; Viral Load | 1999 |
Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Prognosis; Retrospective Studies; Ritonavir | 1999 |
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; Arteriosclerosis; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indinavir; Lipids; Lipoprotein(a); Lipoproteins; Logistic Models; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Thyrotropin | 1999 |
Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series.
Topics: Adolescent; Adult; Aged; Databases, Factual; Female; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Saquinavir; Treatment Outcome; United States; United States Food and Drug Administration; Zidovudine | 1999 |
Effect of protease inhibitors on the sense of taste.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Taste; Taste Disorders | 1999 |
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Flow Cytometry; Fluorescent Dyes; HIV Protease Inhibitors; Humans; Indinavir; Lymphocytes; Nelfinavir; Rhodamine 123; Ritonavir; Saquinavir; Temperature; Verapamil | 1999 |
Inhibition of adipocyte differentiation by HIV protease inhibitors.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Carbamates; Carrier Proteins; Cell Differentiation; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Furans; Gene Expression; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Intercellular Signaling Peptides and Proteins; Lipoprotein Lipase; Mice; Myelin P2 Protein; Nelfinavir; Neoplasm Proteins; Nerve Tissue Proteins; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Ritonavir; Stem Cells; Sulfonamides; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 1999 |
Pharmacokinetic interactions between HIV-protease inhibitors in rats.
Topics: Acquired Immunodeficiency Syndrome; Animals; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; Indinavir; Male; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir | 1999 |
Choosing the best initial therapy for HIV-1 infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Influence of protease inhibitor therapy on lipoprotein metabolism.
Topics: Adult; CD4 Lymphocyte Count; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Lipoproteins; Male; Middle Aged; Nelfinavir; Prospective Studies; Ritonavir; Viral Load | 1999 |
Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Reproducibility of Results; Ritonavir; Saquinavir | 2000 |
The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6.
Topics: HIV Protease Inhibitors; HT29 Cells; Humans; Indinavir; Intestinal Mucosa; Ion Transport; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Virologic response associated with a change in protease inhibitor therapy.
Topics: HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Treatment Outcome | 2000 |
Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.
Topics: Drug Design; Enzymes, Immobilized; HIV Protease; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Kinetics; Molecular Weight; Nelfinavir; Ritonavir; Saquinavir; Surface Plasmon Resonance | 2000 |
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Topics: Antidepressive Agents, Second-Generation; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Microsomes, Liver; Nelfinavir; Oxidoreductases, N-Demethylating; Piperazines; Ritonavir; Saquinavir; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Trazodone | 2000 |
When to switch and what to switch to: strategic use of antiretroviral therapy.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Mutation; Nelfinavir; Practice Guidelines as Topic; Pyrimidinones; Retroviridae; Retroviridae Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors; Treatment Failure; Viral Load | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Zidovudine | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.
Topics: Animals; Cell Line; HIV Protease Inhibitors; Humans; Indinavir; Lung; Male; Microbial Sensitivity Tests; Nelfinavir; Pepstatins; Pneumocystis; Pneumocystis Infections; Rats; Rats, Sprague-Dawley; Saquinavir | 2000 |
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Cohort Studies; Confidence Intervals; Drug Monitoring; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Incidence; Indinavir; Italy; Male; Middle Aged; Multivariate Analysis; Nelfinavir; Prospective Studies; Risk Factors; Ritonavir; Saquinavir | 2000 |
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Transfusion Reaction; Zidovudine | 2000 |
Hyperlipidemia associated with the use of protease inhibitors.
Topics: Adult; Anti-HIV Agents; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Triglycerides | 2000 |
Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carbamates; Dietary Fats; Drug Interactions; Furans; HIV Protease Inhibitors; Indinavir; Injections, Subcutaneous; Insulin; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Saquinavir; Sulfonamides | 2000 |
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Topics: Amino Acid Sequence; Amino Acid Substitution; Carbamates; Codon; Drug Resistance, Microbial; Furans; Global Health; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Phylogeny; Ritonavir; Saquinavir; Sulfonamides | 2000 |
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
Topics: Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutagenesis, Site-Directed; Mutation; Nelfinavir; Polymerase Chain Reaction; Ritonavir; Saquinavir; Virus Replication | 2000 |
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
Topics: Amino Acid Substitution; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Drug Resistance, Microbial; Entropy; Enzyme Stability; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Mutagenesis, Site-Directed; Nelfinavir; Phenylalanine; Protons; Ritonavir; Saquinavir; Thermodynamics; Valine | 2000 |
Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; Indinavir; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir | 2000 |
No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.
Topics: Antimalarials; Antiretroviral Therapy, Highly Active; Drug Interactions; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Malaria; Mefloquine; Nelfinavir | 2000 |
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Depression, Chemical; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyurea; Immunity, Cellular; Indinavir; Lamivudine; Lymphocyte Count; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Refusal; Viral Load; Viremia; Zidovudine | 2001 |
The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Topics: Acetamides; Albumins; Azepines; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Nelfinavir; Ritonavir; Solvents; Structure-Activity Relationship; Sulfonamides; Urea | 2000 |
Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6.
Topics: Acquired Immunodeficiency Syndrome; Colon; Diarrhea; HIV Protease Inhibitors; HT29 Cells; Humans; Indinavir; Intestinal Absorption; Intestinal Mucosa; Nelfinavir; Ritonavir; Saquinavir | 2000 |
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Protease Inhibitors; Humans; Indicators and Reagents; Indinavir; Nelfinavir; Reference Standards; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 2001 |
The safety and antiviral effect of protease inhibitors in children.
Topics: Adolescent; Blood Chemical Analysis; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Male; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Viral Load | 2001 |
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
Topics: Adult; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Resistance, Microbial; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Phenotype; RNA, Viral; Treatment Failure; Viral Load | 2001 |
Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Indinavir; Lamivudine; Nelfinavir; Occupational Exposure; Reverse Transcriptase Inhibitors; Thyroxine; Zidovudine | 2001 |
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
Topics: Adult; Amino Acid Sequence; Catalysis; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Protein Structure, Secondary; Ritonavir; Saquinavir; Uganda | 2001 |
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1998 |
Data on nevirapine combinations released.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Viral Load | 1998 |
Viracept combination studies.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine | 1998 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonic Acids | 1997 |
Update on antivirals.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dosage Forms; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1997 |
Other options: clinical trials.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Selection; Salvage Therapy; Treatment Failure; Viral Load | 1998 |
Combinations of protease inhibitors.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1998 |
Indinavir, nelfinavir -- twice a day?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir | 1998 |
Medical marijuana study in San Francisco: pays $1000, 25 days in hospital.
Topics: Cannabis; Clinical Trials as Topic; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Selection; Phytotherapy; San Francisco | 1998 |
Antiviral update.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Menstrual Cycle; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Viral Load | 1998 |
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Cell Line; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Multidrug Resistance-Associated Proteins; Nelfinavir; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Saquinavir | 2001 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
Topics: Adult; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
Topics: Amino Acid Substitution; Biosensing Techniques; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Kinetics; Mathematics; Mutation; Nelfinavir; Protein Binding; Ritonavir; Saquinavir; Thermodynamics | 2001 |
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides | 2001 |
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Follow-Up Studies; HIV Infections; Humans; Indinavir; Longitudinal Studies; Middle Aged; Nelfinavir; Prevalence; Protease Inhibitors; Ritonavir; Saquinavir; Viral Load | 2001 |
The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Topics: Adipose Tissue; Adult; Aged; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; Saquinavir; Triglycerides | 2001 |
Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.
Topics: Body Mass Index; Bone Density; Cohort Studies; Cross-Sectional Studies; Heart; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Longitudinal Studies; Male; Nelfinavir; Osteocalcin | 2001 |
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Topics: Adult; Antigens, CD34; Antiretroviral Therapy, Highly Active; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fluorescent Dyes; Hematopoietic Stem Cells; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Lymphocytes; Male; Nelfinavir; Rhodamine 123; Ritonavir; RNA, Viral; Saquinavir | 2001 |
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid e
Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; CD4-Positive T-Lymphocytes; Cell Line; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Multidrug Resistance-Associated Proteins; Nelfinavir; Ritonavir; Saquinavir | 2001 |
Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; HIV Protease Inhibitors; Indinavir; Macaca mulatta; Macaca nemestrina; Mycobacterium bovis; Nelfinavir; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes; Tenofovir; Tuberculosis | 2001 |
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Odds Ratio; Patient Compliance; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Surveys and Questionnaires | 2001 |
Antiretroviral rounds. When success is a pain.
Topics: Abdominal Pain; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
Protease inhibitors and blood sugar problems.
Topics: Anti-HIV Agents; Blood Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Nelfinavir | 2001 |
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.
Topics: Carbamates; Cell Survival; Cross-Linking Reagents; Esters; Glucose; Half-Life; HIV Protease Inhibitors; HIV-1; Humans; Hydrolysis; Indinavir; Nelfinavir; Prodrugs; Saquinavir; Tumor Cells, Cultured | 2001 |
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Viremia | 2002 |
Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Base Sequence; CD4 Lymphocyte Count; Drug Resistance, Viral; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral | 2001 |
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Female; Gene Expression; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Kinetics; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Nelfinavir; Ritonavir; Saquinavir | 2002 |
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Furans; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides; Time Factors | 2002 |
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Topics: Adipocytes; Animals; Animals, Newborn; Bone and Bones; Calcium; Carbamates; Cells, Cultured; Down-Regulation; Fats; Furans; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mesoderm; Nelfinavir; Osteoblasts; Osteoclasts; Osteoprotegerin; Pyrimidinones; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Ritonavir; Saquinavir; Skull; Stem Cells; Sulfonamides | 2002 |
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
Topics: Carbamates; Drug Evaluation; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Topics: Acquired Immunodeficiency Syndrome; Binding Sites; Biological Evolution; Computational Biology; Computer Simulation; Computer-Aided Design; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Molecular; Mutation; Nelfinavir; Ritonavir; Saquinavir | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Male sexual dysfunction associated with antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Cohort Studies; Erectile Dysfunction; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Managed Care Programs; Middle Aged; Nelfinavir; New England; Retrospective Studies; Ritonavir; Saquinavir | 2002 |
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Topics: Africa; Amides; Amino Acid Substitution; Anti-HIV Agents; Calorimetry; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Kinetics; Mutagenesis, Site-Directed; Nelfinavir; Phenotype; Polymorphism, Genetic; Recombinant Proteins; Ritonavir; Saquinavir; Thermodynamics; Thiazoles | 2002 |
Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Patient Compliance; Viral Load | 2002 |
Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Topics: Animals; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; Half-Life; HIV Protease Inhibitors; Indinavir; Intestinal Mucosa; Liver; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2002 |
Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Topics: Carbamates; Chromatography, Liquid; Furans; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.
Topics: Animals; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Fusion Proteins, gag-pol; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Inhibitory Concentration 50; Microbial Sensitivity Tests; Nelfinavir; Phenotype; Protein Biosynthesis; Rabbits; Reticulocytes; Time Factors; Transcription, Genetic | 2002 |
[Antiretroviral therapy with nelfinavir for patient infected, by HIV and secondary diabetes mellitus due to indinavir].
Topics: Adult; Diabetes Mellitus; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir | 2002 |
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Body Composition; HIV Protease Inhibitors; Homeostasis; Humans; Indinavir; Insulin; Leptin; Lipids; Lipodystrophy; Magnetic Resonance Imaging; Male; Middle Aged; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.
Topics: Biological Transport; Caco-2 Cells; Epithelial Cells; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Prodrugs; Saquinavir | 2002 |
Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.
Topics: Adipocytes; Cell Line; Deoxyglucose; Drug Administration Schedule; Fibroblasts; Glucose Transporter Type 1; HIV Protease Inhibitors; Humans; Indinavir; Insulin Resistance; Lipolysis; Monosaccharide Transport Proteins; Muscle, Skeletal; Nelfinavir; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Saquinavir | 2003 |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity.
Topics: Animals; Anti-Infective Agents; Drug Interactions; Glomerular Filtration Rate; HIV Protease Inhibitors; Indinavir; Kidney Diseases; Male; Nelfinavir; Rats; Rats, Wistar; Renal Circulation; Trimethoprim, Sulfamethoxazole Drug Combination; Vasoconstriction | 2002 |
Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Topics: Animals; Carbamates; Drug Interactions; Furans; Indinavir; Infusions, Intravenous; Intestinal Absorption; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2003 |
Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Drug Interactions; fas Receptor; HIV Protease Inhibitors; Humans; Indinavir; Jurkat Cells; Nelfinavir; Ritonavir; Saquinavir; Tumor Necrosis Factor-alpha; U937 Cells | 2003 |
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Bone Remodeling; Calcitriol; Cell Line; Cholestanetriol 26-Monooxygenase; Cytochrome P-450 Enzyme System; Depression, Chemical; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Macrophages; Nelfinavir; Ritonavir; Steroid Hydroxylases; Vitamin D; Vitamin D3 24-Hydroxylase | 2003 |
[HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
Topics: Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Italy; Male; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy | 2002 |
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; Heparin; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2003 |
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Topics: Adult; Arteriosclerosis; Biomarkers; Black People; C-Reactive Protein; Calcium; Cholesterol; Coronary Artery Disease; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir | 2003 |
Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.
Topics: Adult; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydrocortisone; Indinavir; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Viral Load | 2003 |
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
Topics: Animals; Carbamates; Cells, Cultured; Furans; Glucose; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Nelfinavir; Ritonavir; Sulfonamides | 2003 |
Characterizing classes of antiretroviral drugs by genotype.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cluster Analysis; Genotype; HIV Infections; HIV-1; Humans; Indinavir; Models, Genetic; Models, Statistical; Molecular Sequence Data; Nelfinavir | 2003 |
Summaries for patients. Does marijuana affect viral loads in people with HIV?
Topics: Administration, Oral; Cannabinoids; Dronabinol; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; RNA, Viral; Viral Load | 2003 |
HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.
Topics: Animals; Bone Diseases, Metabolic; Bone Resorption; Carrier Proteins; CD3 Complex; Cell Line; Cells, Cultured; Cysteine Endopeptidases; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; HIV Envelope Protein gp120; HIV Protease Inhibitors; Humans; Immunoblotting; Indinavir; Interferon-gamma; Membrane Glycoproteins; Mice; Multienzyme Complexes; Nelfinavir; Osteoclasts; Precipitin Tests; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Binding; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Ritonavir | 2003 |
Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults.
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 2003 |
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Carbamates; Cell Differentiation; Cell Line; Enzyme-Linked Immunosorbent Assay; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Mice; Mice, Inbred Strains; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV-2; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Patient Compliance; Viral Load | 2003 |
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Western; Carbamates; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Nucleus; DNA-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Lamin Type A; Mice; Microscopy, Confocal; Nelfinavir; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Transcription Factors | 2003 |
Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.
Topics: Adult; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir | 2003 |
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Topics: Biotransformation; Cohort Studies; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2003 |
Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
Topics: Anti-HIV Agents; Cell Line; Half-Life; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Magnetic Resonance Spectroscopy; Molecular Structure; Nelfinavir; Prodrugs; Saquinavir | 2004 |
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression; HIV Protease Inhibitors; Humans; Indinavir; Mitoxantrone; Nelfinavir; Neoplasm Proteins; Ritonavir; Saquinavir; Tritium | 2004 |
Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing.
Topics: Adult; Child; Drug Therapy, Combination; France; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Protease Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2004 |
Direct interference of HIV protease inhibitors with pancreatic beta-cell function.
Topics: Animals; Calcium; Calcium Channels; Cells, Cultured; Glucose; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Islets of Langerhans; Membrane Potentials; Mice; Nelfinavir; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Radioimmunoassay; Ritonavir | 2004 |
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Chi-Square Distribution; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Retrospective Studies; Treatment Outcome; Viral Load | 2004 |
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides | 2004 |
HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants.
Topics: Acetylcysteine; Alkynes; Antioxidants; Antiretroviral Therapy, Highly Active; Benzoxazines; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Cyclopropanes; Endothelial Cells; Endothelium, Vascular; Gene Expression; Glutathione; Humans; Indinavir; Interleukin-1; Leukocytes, Mononuclear; Nelfinavir; Oxazines; Oxidative Stress; Reactive Oxygen Species; Tumor Necrosis Factor-alpha; Zidovudine | 2004 |
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Lopinavir; Male; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Saquinavir; Treatment Outcome | 2004 |
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Topics: Carbamates; Cell Line; Furans; Glucose; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Nelfinavir; Phosphoproteins; Phosphorylation; Ritonavir; Saquinavir; Signal Transduction; Stimulation, Chemical; Sulfonamides; Time Factors | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nelfinavir; Prednisone; Prospective Studies; Vincristine | 2005 |
Postexposure prophylaxis after sexual assaults: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Brazil; Child; Child, Preschool; Cohort Studies; Drug Administration Schedule; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Prospective Studies; Rape; Sexually Transmitted Diseases; Zidovudine | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Cell Differentiation; Fibrinolytic Agents; HIV Protease Inhibitors; Indinavir; Intercellular Signaling Peptides and Proteins; Interleukin-6; Mice; Nelfinavir; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Zidovudine | 2005 |
TDM: therapeutic drug measuring or therapeutic drug monitoring?
Topics: Anti-Retroviral Agents; Carbamazepine; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; HIV Infections; Humans; Indinavir; Nelfinavir; Nevirapine; Patient Compliance; Quality Control; Surveys and Questionnaires | 2005 |
Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
Topics: Animals; Bradykinin; Carbamates; Coronary Vessels; Down-Regulation; Furans; HIV Protease Inhibitors; Indinavir; Methionine; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Nelfinavir; Nitric Oxide Synthase; Organ Culture Techniques; Ritonavir; RNA, Messenger; Saquinavir; Selenium Compounds; Sulfonamides; Superoxides; Swine; Vasomotor System | 2005 |
HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Action Potentials; Animals; Anions; Calcium; Cell Membrane; Clotrimazole; Electrophysiology; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Insulin-Secreting Cells; Ion Channels; Membrane Potentials; Mice; Nelfinavir; Patch-Clamp Techniques; Potassium Channel Blockers; Ritonavir; Tetraethylammonium | 2006 |
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Indinavir; Isoenzymes; Kinetics; Nelfinavir; Recombinant Proteins; Ritonavir; Saquinavir; Sulfonamides; Testosterone | 2006 |
Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Lopinavir; Microbial Sensitivity Tests; Mutation; Nelfinavir; Pyrimidinones; Species Specificity; Virus Replication | 2006 |
Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Pressure; Body Mass Index; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Protease Inhibitors; Humans; Hypertension; Indinavir; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nelfinavir; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Female; HIV Infections; Humans; Indinavir; Liver; Male; Nelfinavir; Nevirapine; Ritonavir; Sex Factors | 2006 |
Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.
Topics: Ascomycota; Culture Media; Enzyme Activation; Fungal Proteins; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Indinavir; Mycelium; Nelfinavir; Pepstatins; Peptide Hydrolases; Ritonavir; Saquinavir; Time Factors | 2006 |
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.
Topics: Algorithms; Bayes Theorem; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Genetic; Nelfinavir; Phenotype; Polymorphism, Genetic; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2006 |
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays | 2007 |
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genetic Variation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Orosomucoid; Oxazines; Phenotype; Pyrimidinones; Ritonavir; Switzerland | 2006 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
Topics: Bayes Theorem; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Saquinavir | 2007 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4-Positive T-Lymphocytes; DNA, Viral; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Leukocytes, Mononuclear; Middle Aged; Nelfinavir; Polymerase Chain Reaction; RNA, Viral; Viral Load | 2007 |
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.
Topics: Alkaline Phosphatase; Calcium; Cell Line; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oligonucleotide Array Sequence Analysis; Osteoblasts; Ritonavir; Saquinavir; Tissue Inhibitor of Metalloproteinase-3; Up-Regulation | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.
Topics: Adult; Biopsy; Cell Nucleus Shape; Cells, Cultured; Cellular Senescence; Child; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Female; Fibroblasts; HIV Protease Inhibitors; Humans; Indinavir; Lamin Type A; Lipodystrophy, Familial Partial; Middle Aged; Mitochondria; Mutation; Nelfinavir; Nuclear Proteins; Oxidative Stress; Protein Precursors; Reactive Oxygen Species | 2007 |
The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.
Topics: HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Kinetics; Mutant Proteins; Nelfinavir; Polymorphism, Genetic; Sequence Analysis, Protein; Static Electricity | 2008 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.
Topics: Aspartic Acid Endopeptidases; Cell Survival; Cells, Cultured; Cerebral Arteries; Cerebral Veins; Endothelial Cells; Frontal Lobe; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxidative Stress; Phosphorylation; Proto-Oncogene Proteins; Reactive Oxygen Species; Receptor, Notch1; Receptor, Notch4; Receptors, Notch; Repressor Proteins; Ritonavir; Saquinavir; Vitamin E | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation, Missense; Nelfinavir; Portugal; Saquinavir; Selection, Genetic | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.
Topics: Antimalarials; Artemisinins; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Malaria; Nelfinavir | 2010 |
Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cells, Cultured; Fluoresceins; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides | 2010 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.
Topics: Animals; Anti-Retroviral Agents; Apoptosis; Body Weight; Cell Membrane Permeability; Cell Proliferation; Didanosine; HIV Protease Inhibitors; Indinavir; Intestinal Absorption; Intestinal Mucosa; Male; Mice; Models, Animal; Necrosis; Nelfinavir; Reverse Transcriptase Inhibitors; Survival Rate; Water-Electrolyte Balance; Zidovudine | 2010 |
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome | 2011 |
The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes.
Topics: Animals; Animals, Newborn; Astrocytes; Brain Chemistry; Cell Survival; Cells, Cultured; Glucose; Glutathione; HIV Protease Inhibitors; Hydrogen Peroxide; Indinavir; Lactic Acid; Leukotriene Antagonists; Multidrug Resistance-Associated Proteins; Nelfinavir; Oxidative Stress; Propionates; Quinolines; Rats; Rats, Wistar; Reactive Oxygen Species; Reverse Transcriptase Inhibitors | 2012 |
The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes.
Topics: Animals; Astrocytes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cells, Cultured; Drug Combinations; Glutathione; HIV Protease Inhibitors; Indinavir; Nelfinavir; Propionates; Quinolines; Rats; Rats, Wistar; Ritonavir | 2013 |
Indinavir and nelfinavir inhibit proximal insulin receptor signaling and salicylate abrogates inhibition: potential role of the NFkappa B pathway.
Topics: 3T3-L1 Cells; Adaptor Proteins, Signal Transducing; Animals; Anti-Infective Agents; CHO Cells; Cricetinae; Cricetulus; HIV Protease Inhibitors; Humans; Indinavir; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Nelfinavir; NF-kappa B; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Insulin; Salicylic Acid; Signal Transduction | 2013 |
Antiretroviral protease inhibitors accelerate glutathione export from viable cultured rat neurons.
Topics: Cells, Cultured; Glutathione; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Neurons; Ritonavir | 2014 |
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.
Topics: Animals; Anti-HIV Agents; Aspartic Acid Proteases; Carbamates; Furans; Host-Parasite Interactions; Indinavir; Insect Vectors; Lopinavir; Microscopy, Electron, Transmission; Nelfinavir; Protease Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Trypanocidal Agents; Trypanosoma cruzi | 2014 |
Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.
Topics: Animals; Bilirubin; Carrier Proteins; Chemical and Drug Induced Liver Injury; Computer Simulation; Enzyme Inhibitors; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Liver; Mice; Mice, Knockout; Models, Biological; Nelfinavir; Pharmacokinetics; Rats; Rats, Gunn; Receptors, Chemokine; Systems Biology | 2017 |
Insulin modulates hippocampally-mediated spatial working memory via glucose transporter-4.
Topics: Animals; Atazanavir Sulfate; Glucose; Glucose Transporter Type 4; Hippocampus; Indinavir; Insulin; Male; Memory, Short-Term; Microinjections; Nelfinavir; Rats; Rats, Sprague-Dawley; Signal Transduction; Spatial Memory | 2018 |
The mechanism for differential effect of nelfinavir and indinavir on collagen metabolism in human skin fibroblasts.
Topics: Acetylcysteine; Ascorbic Acid; Cell Survival; Collagen; Dipeptidases; DNA; Down-Regulation; Fibroblasts; Glutamine; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; NF-kappa B p50 Subunit; Phosphatidylinositol 3-Kinases; Phosphorylation; Proline; Skin; Wortmannin | 2019 |
Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Furans; HIV Protease; Indinavir; Molecular Conformation; Molecular Dynamics Simulation; Mutation; Nelfinavir; Protein Binding; Ritonavir; Sulfonamides | 2020 |
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
Topics: Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Drug Stability; HIV Protease Inhibitors; In Vitro Techniques; Magnetic Resonance Spectroscopy; Prodrugs; Valine | 2008 |